Aussie firm says it can help erectile problems, but not cure them
The Aussie erectile disorder treatment firm, O2A, has announced it is looking to help patients overcome the problem by injecting a drug into their bloodstream, instead of having surgery.
The company, which also provides other forms of treatment to men who suffer from the condition, said its new treatment injects the drug directly into the veins and arteries of its patients.
“This means it can work for a period of time before it has to be surgically removed, meaning it is not a one-off treatment that needs to be followed up,” O2C CEO Tim Stapleton said.
The drug is made by the company’s own drug company, Medibank, and it is now being tested in trials across the country.
O2A says it was the first Australian firm to offer a treatment for erectile function in a clinical trial.
“It was very successful,” Mr Staperton said.
“We were able to provide a therapeutic product that worked and we’re confident that it will work in a number of other cases.”
The company has done a very good job and we are very confident that we will be able to continue doing so in the future.
The drug has also been approved by the Food and Drug Administration in New Zealand.”
[It is] not a treatment that is going to cure anything, but it is going in the right direction,” he said.
The drug has also been approved by the Food and Drug Administration in New Zealand.
The firm says the drug has the potential to help many other men who have problems with their erectile functions.
“For many, erectile difficulties are associated with an inability to have sexual intercourse,” Mr Southey said.”[It’s] a condition that affects approximately one in five Australians.”
“There are several things that can be done to reduce the risk of erectile impairment, and the most important thing to do is get regular exercise and the right support to help reduce the likelihood of this condition.”
The drug, called MCT, can help treat erectile issues in patients who have other types of disorders, such as men with cystic fibrosis or cardiovascular disease.
The O2D clinical trial will be conducted in New South Wales, South Australia, Western Australia, Victoria, Queensland and Western Australia.
The trial is set to run for a year.
O2C is also offering the drug in other countries including the United States and the United Kingdom.